Skip to main content
Top
Published in: BMC Nephrology 1/2015

Open Access 01-12-2015 | Research article

An observational study of the quality of care for chronic kidney disease: a Buffalo and Albany, New York metropolitan area study

Authors: Pradeep Arora, Peter L. Elkin, Joseph Eberle, J. James Bono, Laura Argauer, Brian M. Murray, Raghu Ram, Rocco C. Venuto

Published in: BMC Nephrology | Issue 1/2015

Login to get access

Abstract

Background

The database of a major regional health insurer was employed to identify the number and frequency of covered patients with chronic kidney disease (CKD). We then examined the characteristics of their care as defined, in part, by the frequency of physician visits and specialty referral, the characteristics of laboratory testing and total costs as indices of the quality of care of the subject population.

Methods

This retrospective, cross-sectional study analyzed insurance claims, laboratory results and medication prescription data. Patients with two estimated glomerular filtration rate readings below 60 ml/min/1.73 m2 (n = 20,388) were identified and classified by CKD stage.

Results

The prevalence of CKD stages 3a and above was 12 %. Vascular comorbidities were common with prevalence increasing steadily from stage 3a through stage 5. Only 55.6 % of stage 4 CKD patients had claims for nephrology visits within one year of their index date. Fifty-nine percent of patients had claims for renin-angiotensin system (RAS) blockers. Twenty-five percent of patients in stage 3a CKD filled a prescription for non-steroidal anti-inflammatory drugs. Fifty-two percent of patients who developed end-stage renal disease received their first dialysis treatment as inpatients.

Conclusions

The pattern of medical practice observed highlights apparent deficiencies in the care of CKD patients including inappropriate medication use, delayed nephrology referral, and a lack of preparation for dialysis. This study shows the potential value of using large patient databases available through insurers to assess and likely improve regional CKD care.
Literature
1.
go back to reference Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1–12. doi:10.1053/ajkd.2003.50007.CrossRefPubMed Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1–12. doi:10.​1053/​ajkd.​2003.​50007.CrossRefPubMed
3.
4.
go back to reference U.S. Renal Data System. USRDS 2004 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United State. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004. U.S. Renal Data System. USRDS 2004 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United State. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004.
5.
go back to reference U.S. Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United State. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012. p. 2012. U.S. Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United State. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012. p. 2012.
7.
go back to reference Wish J, Schulman K, Law A, Nassar G. Healthcare expenditures and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis. Kidney Blood Press Res. 2003;32:110–8. doi:10.1159/000213166.CrossRef Wish J, Schulman K, Law A, Nassar G. Healthcare expenditures and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis. Kidney Blood Press Res. 2003;32:110–8. doi:10.​1159/​000213166.CrossRef
9.
go back to reference Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors--United States, 1999–2004. MMWR Morb Mortal Wkly Rep. 2007;56(8):161–5. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors--United States, 1999–2004. MMWR Morb Mortal Wkly Rep. 2007;56(8):161–5.
13.
go back to reference Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–47.CrossRefPubMed Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–47.CrossRefPubMed
14.
go back to reference Owen Jr WF. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol. 2003;14(7 Suppl 2):S76–80.CrossRefPubMed Owen Jr WF. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol. 2003;14(7 Suppl 2):S76–80.CrossRefPubMed
17.
go back to reference Daien V, Duny Y, Ribstein J, du Cailar G, Mimran A, Villain M, et al. Treatment of hypertension with renin-angiotensin system inhibitors and renal dysfunction: a systematic review and meta-analysis. Am J Hypertens. 2012;25(1):126–32. doi:10.1038/ajh.2011.180.CrossRefPubMed Daien V, Duny Y, Ribstein J, du Cailar G, Mimran A, Villain M, et al. Treatment of hypertension with renin-angiotensin system inhibitors and renal dysfunction: a systematic review and meta-analysis. Am J Hypertens. 2012;25(1):126–32. doi:10.​1038/​ajh.​2011.​180.CrossRefPubMed
18.
go back to reference Kunz R, Friedrich C, Wolbers M, Mann JFE. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30–48.CrossRefPubMed Kunz R, Friedrich C, Wolbers M, Mann JFE. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30–48.CrossRefPubMed
19.
go back to reference O’Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med. 2009;150(10):717–24.CrossRefPubMed O’Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med. 2009;150(10):717–24.CrossRefPubMed
20.
go back to reference Qaseem A, Hopkins Jr RH, Sweet DE, Starkey M, Shekelle P. Clinical Guidelines Committee of the American College of Physicians. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(12):835–47. doi:10.7326/0003-4819-159-12-201312170-00726.PubMed Qaseem A, Hopkins Jr RH, Sweet DE, Starkey M, Shekelle P. Clinical Guidelines Committee of the American College of Physicians. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(12):835–47. doi:10.​7326/​0003-4819-159-12-201312170-00726.PubMed
21.
go back to reference Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001;12(7):1501–7.PubMed Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001;12(7):1501–7.PubMed
22.
go back to reference Ang GY, Heng BH, Liew AS, Chong PN. Quality of care of patients with chronic kidney disease in national healthcare group polyclinics from 2007 to 2011. Ann Acad Med Singapore. 2013;42(12):632–9.PubMed Ang GY, Heng BH, Liew AS, Chong PN. Quality of care of patients with chronic kidney disease in national healthcare group polyclinics from 2007 to 2011. Ann Acad Med Singapore. 2013;42(12):632–9.PubMed
25.
go back to reference Möller B, Pruijm M, Adler S, Scherer A, Villiger PM, Finckh A. Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) Foundation, CH-8048 Zurich, Switzerland. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis. 2015; 74(4):718–23. doi:10.1136/annrheumdis-2013-204078.CrossRefPubMed Möller B, Pruijm M, Adler S, Scherer A, Villiger PM, Finckh A. Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) Foundation, CH-8048 Zurich, Switzerland. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis. 2015; 74(4):718–23. doi:10.​1136/​annrheumdis-2013-204078.CrossRefPubMed
26.
go back to reference McCullough PA, Brown WW, Gannon MR,Vassalotti JA, Collins AJ, Chen SC, et al. Sustainable Community-Based CKD Screening Methods Employed by the National Kidney Foundation’s Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011;57(3):S4–8.CrossRefPubMed McCullough PA, Brown WW, Gannon MR,Vassalotti JA, Collins AJ, Chen SC, et al. Sustainable Community-Based CKD Screening Methods Employed by the National Kidney Foundation’s Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011;57(3):S4–8.CrossRefPubMed
27.
go back to reference Arora P, Obrador GT, Ruthazer R, Kausz AT, Meyer KB, Jenuleson CS, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol. 1999;10(6):1281–6.PubMed Arora P, Obrador GT, Ruthazer R, Kausz AT, Meyer KB, Jenuleson CS, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol. 1999;10(6):1281–6.PubMed
28.
go back to reference Kazmi WH, Obrador GT, Khan SS, Pereira BJG, Kausz AT. Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. Nephrol Dial Transplant. 2004;19(7):1808–14. doi:10.1093/ndt/gfg573.CrossRefPubMed Kazmi WH, Obrador GT, Khan SS, Pereira BJG, Kausz AT. Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. Nephrol Dial Transplant. 2004;19(7):1808–14. doi:10.​1093/​ndt/​gfg573.CrossRefPubMed
29.
go back to reference Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137(6):479–86.CrossRefPubMed Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137(6):479–86.CrossRefPubMed
33.
go back to reference Murff HJ, FitzHenry F, Matheny ME, Gentry N, Kotter KL, Crimin K, et al. Automated identification of postoperative complications within an electronic medical record using natural language processing. JAMA. 2011;306(8):848–55. doi:10.1001/jama.2011.1204.CrossRefPubMed Murff HJ, FitzHenry F, Matheny ME, Gentry N, Kotter KL, Crimin K, et al. Automated identification of postoperative complications within an electronic medical record using natural language processing. JAMA. 2011;306(8):848–55. doi:10.​1001/​jama.​2011.​1204.CrossRefPubMed
Metadata
Title
An observational study of the quality of care for chronic kidney disease: a Buffalo and Albany, New York metropolitan area study
Authors
Pradeep Arora
Peter L. Elkin
Joseph Eberle
J. James Bono
Laura Argauer
Brian M. Murray
Raghu Ram
Rocco C. Venuto
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2015
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-015-0194-2

Other articles of this Issue 1/2015

BMC Nephrology 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.